Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silexion Therapeutics ( (SLXN) ) has issued an announcement.
On September 11, 2025, Silexion Therapeutics announced positive preclinical data for their drug SIL204, which shows effective distribution and anti-tumor activity in major metastatic sites of pancreatic cancer. The results validate their dual-route administration strategy, combining intratumoral and systemic delivery, and support the planned initiation of Phase 2/3 trials in the first half of 2026, with regulatory submissions expected in late 2025 and early 2026.
The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for solid tumor cancers driven by the KRAS oncogene, which is a common oncogenic gene driver in human cancers. The company is dedicated to advancing therapeutic options in oncology, particularly for locally advanced pancreatic cancer.
Average Trading Volume: 76,229
Technical Sentiment Signal: Sell
Current Market Cap: $3.28M
Find detailed analytics on SLXN stock on TipRanks’ Stock Analysis page.